| Domain | Summary |
|---|---|
| Identifiers/synonyms | - Dyskeratosis congenita (DC) is also referred to as **Zinsser–Cole–Engman syndrome** in retrieved sources.<br>- It is classified as a **telomere biology disorder (TBD)** / short-telomere syndrome.<br>- Formal **OMIM, Orphanet, ICD-10/11, MeSH, MONDO** codes were **not in retrieved full-text evidence**. (pqac-00000002, pqac-00000003, pqac-00000006) |
| Core definition | - DC is an **ultra-rare inherited multisystem bone marrow failure syndrome** caused principally by defects in **telomere maintenance**.<br>- The classic diagnostic triad is **nail dystrophy, abnormal/reticulated skin pigmentation, and oral leukoplakia**.<br>- Bone marrow failure and cancer predisposition are central disease-defining complications. (pqac-00000000, pqac-00000004, pqac-00000005, pqac-00000006) |
| Key phenotypes & frequencies | - Mucocutaneous triad frequencies reported in one 2023 review: **reticulated pigmentation ~90%, nail dystrophy ~88%, leukoplakia ~80%**.<br>- Bone marrow failure is a hallmark; some sources report **>90% by age 40**.<br>- Extra-hematologic disease includes **pulmonary fibrosis/interstitial lung disease**, **liver disease/portal hypertension**, premature hair graying, and cancer susceptibility; pulmonary fibrosis occurs in about **20%** in one review. (pqac-00000022, pqac-00000018, pqac-00000016, pqac-00000017, pqac-00000021) |
| Natural history stats | - In a pediatric cohort (n=14), diagnosis occurred at **median age 8.5 years**; **13/14** progressed to bone marrow failure at **median age 8 years**.<br>- In the same cohort, **6/14 died**, at **median age 13 years**; all had hematologic manifestations at diagnosis and non-hematologic manifestations accumulated over follow-up.<br>- Adult/cryptic TBD can present later with isolated hematologic, pulmonary, or liver disease rather than the full triad. (pqac-00000020, pqac-00000006, pqac-00000021) |
| Key causal genes & new 2024 findings | - Established genes in retrieved evidence include **DKC1, TERC, TERT, TINF2, RTEL1, NOP10, NHP2, CTC1, ACD/TPP1, PARN, WRAP53/TCAB1, DCLRE1B, RPA1, NPM1, NAF1** and others; inheritance can be **X-linked, autosomal dominant, or autosomal recessive**.<br>- A 2024 EMBO Molecular Medicine study reported that about **35%** of clinically diagnosed cases remain genetically unresolved and expanded the allelic architecture with **POLA1** (novel X-linked gene), plus additional **POT1** and **ZCCHC8** variants.<br>- Functional data linked new variants to disrupted **primase/CST/shelterin interactions**, reduced POLA1 catalytic activity, reduced POT1 binding to telomeric ssDNA, and ZCCHC8 deficiency with pervasive transcription/inflammation. (pqac-00000008, pqac-00000012, pqac-00000013, pqac-00000015) |
| Diagnostics (telomere length testing thresholds, screening yields) | - **Flow-FISH lymphocyte telomere length** is the current preferred functional screening test; a commonly used threshold is **<1st percentile for age** for strong support of TBD/DC diagnosis.<br>- In adults, one 2023 prospective cohort used standard suspicion criteria of **<10th percentile for age** and an extended criterion of **<6.5 kb in patients >40 years**.<br>- In 262 screened adults, shortened TL was found in **120**; among standard-screened patients with NGS material, **17/76 (22.4%)** had pathogenic/likely pathogenic variants and **17/76 (22.4%)** had VUS; main genes were **TERT, TERC, RTEL1**. (pqac-00000005, pqac-00000023, pqac-00000024, pqac-00000025, pqac-00000028, pqac-00000030) |
| Treatments (androgens, HSCT, organ transplant considerations) | - **Androgens** (especially **danazol**, also oxymetholone/nandrolone) can improve counts; reported hematologic response rates range about **50–100%** short-term, with one study showing **11/12** patients gained telomere length (**mean +386 bp**) and **83% hematologic response at 24 months**.<br>- **HSCT/allo-HCT** is the only curative therapy for marrow failure/clonal evolution, but transplant morbidity is substantial; **reduced-intensity** and **radiation-avoiding** approaches are favored, and related donors carrying the familial defect should be avoided.<br>- Organ transplantation (especially **lung** and **liver**) may be required for end-organ failure, but telomere disorders increase risk of hematologic and immunosuppression-related complications. (pqac-00000031, pqac-00000034, pqac-00000036, pqac-00000032) |
| Epidemiology | - DC is consistently described as **ultra-rare/rare**.<br>- Retrieved prevalence estimates were approximately **1 case per 1,000,000** in one source and **1–9 per 1,000,000** in another review.<br>- One review noted marked male predominance in historical series (**male:female ~13:1**), though this may reflect enrichment of **X-linked DKC1** disease in some cohorts. (pqac-00000000, pqac-00000003, pqac-00000022) |


*Table: This table condenses the most actionable facts on dyskeratosis congenita and related telomere biology disorders from the retrieved evidence, including definition, phenotype spectrum, genetics, diagnostics, treatment, and epidemiology. It is designed to support rapid knowledge-base curation with source-linked statements.*